Sugi Predict

Sugi Predict / Compounds / SCHEMBL341606

SCHEMBL341606

SCHEMBL341606

CCOC(=O)c1cc(CO)cc(C(=O)OCC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA12 O43570 3/20 0.60
▸ CA1 P00915 3/20 0.60
▸ CA2 P00918 3/20 0.60
▸ CA7 P43166 3/20 0.60
▸ CA9 Q16790 3/20 0.60
▸ CA14 Q9ULX7 3/20 0.60
▸ PRKCA P17252 3/20 0.54
▸ PRKCD Q05655 3/20 0.54
▸ CYP4F2 P78329 1/20 0.53
▸ CYP4A11 Q02928 1/20 0.53
▸ CYP2C19 P33261 2/20 0.51
▸ CYP2C9 P11712 1/20 0.51
▸ ESR1 P03372 1/20 0.50
▸ ESR2 Q92731 1/20 0.50
▸ CYP1A2 P05177 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ MAOA P21397 1/20 0.48
▸ HPGD P15428 1/20 0.47
▸ HTT P42858 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14209370 0.93 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL3349112 0.93 CYP2C19 (0.58) CA12CA1CA2CA7CA9
SCHEMBL13307492 0.91 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL16098497 0.89 CA12 (0.53) CA12CA1CA2CA7CA9
SCHEMBL3855642 0.88 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL13307502 0.88 CA12 (0.49) CA12CA1CA2CA7CA9
SCHEMBL19115362 0.88 CA12 (0.51) CA12CA1CA2CA7CA9
SCHEMBL10290650 0.88 CA12 (0.64) CA12CA1CA2CA7CA9
SCHEMBL1664013 0.87 CA12 (0.75) CA12CA1CA2CA7CA9
SCHEMBL12051851 0.86 CA12 (0.58) CA12CA1CA2CA7CA9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 215 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-5908723-A Recording sheets XEROX CORPORATION (US) 1999-06-01 — — US claimed
EP-1911814-B2 Methods for preparing curable pigment inkjet ink sets AGFA NV (BE) 2023-07-12 — — EP disclosed
EP-2740773-B2 Curable pigment inkjet ink sets and methods for preparing the said ink sets AGFA NV (BE) 2022-10-05 — — EP disclosed
EP-3608308-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2021-07-21 — — EP disclosed
CN-107879960-B Lipids and lipid compositions for delivery of active ingredients 诺华股份有限公司 2021-06-22 — — CN disclosed
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-10-06 — — US disclosed
US-10729775-B2 Lipids and lipid compositions for the delivery of active agents NOVARTIS AG (CH) 2020-08-04 — — US disclosed
EP-3608308-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS Novartis AG (CH) 2020-02-12 — — EP disclosed
EP-2964608-B1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS AG (CH) 2019-08-28 — — EP disclosed
US-20180369386-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH INC. 2018-12-27 — — US disclosed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 — — WO disclosed
EP-1149069-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2001-10-31 — — EP disclosed
EP-1144415-A2 FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS WARNER-LAMBERT COMPANY (US) 2001-10-17 — — EP disclosed
WO-2001051689-A1 BIOMOLECULES HAVING MULTIPLE ATTACHMENT MOIETIES FOR BINDING TO A SUBSTRATE SURFACE NANOGEN RECOGNOMICS GMBH (DE) 2001-07-19 — — WO disclosed
US-6242644-B1 FOR TREATING THROMBOSIS, APOPLEXY, CARDIAC INFARCTION, INFLAMATION AND ARTHEROSCLEROSIS HOFFMANN-LA ROCHE INC. 2001-06-05 — — US disclosed
US-20010001799-A1 N-(4- carbamimidoyl-phenyl) -glycine derivatives ACKERMANN JEAN (CH) 2001-05-24 — — US disclosed
WO-2000078708-A1 SUBSTITUTED BENZAMIDE INHIBITORS OF RHINOVIRUS 3C PROTEASE AGOURON PHARMACEUTICALS, INC. (US) 2000-12-28 — — WO disclosed
WO-2000042045-A2 FUNCTIONALIZED HETEROCYCLES AS CHEMOKINE RECEPTOR MODULATORS WARNER-LAMBERT COMPANY (US) 2000-07-20 — — WO disclosed
WO-2000035858-A1 PHENYLGLYCINE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2000-06-22 — — WO disclosed
US-5908723-A Recording sheets XEROX CORPORATION (US) 1999-06-01 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180369386-A1 LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTS LIPA, LPAR1, LPAR4 CA12 2955/4885CA1 2692/4885CA2 1120/4885
US-20010001799-A1 N-(4- carbamimidoyl-phenyl) -glycine derivatives GLRA1, NGLY1, GLS CA12 1856/4885CA1 311/4885CA2 115/4885
US-10792361-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 CA12 2955/4885CA1 2692/4885CA2 1120/4885
US-10729775-B2 Lipids and lipid compositions for the delivery of active agents LIPA, LPAR1, LPAR4 CA12 2955/4885CA1 2692/4885CA2 1120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.